Goldline Pharmaceutical Limited (BOM:544759)

Goldline Pharmaceutical Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	5.92	12.4	7.9	0.54	1.41
Cash & Short-Term Investments	5.92	12.4	7.9	0.54	1.41
Cash Growth	-52.21%	56.94%	1357.38%	-61.58%	42.44%
Accounts Receivable	161.28	106.93	96.22	86.27	86.91
Receivables	161.28	106.93	109.84	107.05	86.91
Inventory	62.12	67.77	74.91	53.7	54.61
Other Current Assets	31.16	45.47	2.36	6.94	34.15
Total Current Assets	260.48	232.57	195	168.23	177.07
Property, Plant & Equipment	26.49	28.37	33.65	24.67	20.96
Long-Term Investments	0.25	0.25	-	0.34	0.34
Other Intangible Assets	0.56	0.53	0.63	0.58	0.58
Long-Term Deferred Tax Assets	0.77	-	-	-	-
Other Long-Term Assets	0.16	0.16	0.07	0.07	3.58
Total Assets	288.71	261.87	229.35	193.88	202.53

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	18.51	20.57	16.44	8.68	15.94
Accrued Expenses	10.24	7.89	6.06	7.69	13.18
Short-Term Debt	59.5	56.5	57.26	49.55	44.22
Current Portion of Long-Term Debt	17.48	21.92	13.52	20.63	-
Current Income Taxes Payable	13.88	9.91	6.73	1.36	-
Other Current Liabilities	1.53	0.86	1.65	2.07	1.34
Total Current Liabilities	121.14	117.65	101.66	89.97	74.69
Long-Term Debt	14.63	31.93	40.52	38.11	58.91
Pension & Post-Retirement Benefits	8.25	6.6	5.74	4.61	-
Long-Term Deferred Tax Liabilities	-	0.89	0.56	0.09	-
Other Long-Term Liabilities	2.2	2.2	2.2	2.2	-
Total Liabilities	146.21	159.27	150.69	134.98	133.59

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	69	23	23	20	20
Additional Paid-In Capital	-	-	-	-	20
Retained Earnings	55.43	15.53	37.58	20.83	10.87
Comprehensive Income & Other	-	46	-	-	-
Total Common Equity	124.43	84.53	60.58	40.83	50.87
Shareholders' Equity	142.5	102.6	78.65	58.9	68.94
Total Liabilities & Equity	288.71	261.87	229.35	193.88	202.53

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	91.62	110.34	111.3	108.29	103.13
Net Cash (Debt)	-85.69	-97.95	-103.4	-107.75	-101.72
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-12.42	-14.20	-17.23	-17.96	-16.97
Filing Date Shares Outstanding	6.9	6.9	6.9	6	6
Total Common Shares Outstanding	6.9	6.9	6.9	6	6
Working Capital	139.35	114.92	93.34	78.26	102.39
Book Value Per Share	18.03	12.25	8.78	6.81	8.48
Tangible Book Value	123.87	84	59.95	40.25	50.29
Tangible Book Value Per Share	17.95	12.17	8.69	6.71	8.38
Land	-	-	4.7	4.7	-
Buildings	14.6	14.6	-	-	-
Machinery	22.46	21.92	20.55	14.6	-
Construction In Progress	-	-	4.48	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 21, 2026

Data Sources Report a data error